SEC Form 4 · accession 0000899243-18-011505
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Watkins
Director
Period of report
May 3, 2018
Accepted (ET)
May 4, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 3, 2018 | M | 15,000 | $4.98 | A | 20,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.98 | May 3, 2018 | M | 15,000 | A | — | May 7, 2018 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1The options vested in 12 equal monthly installments beginning on June 8, 2008.